Evidence map›Paper›PMID 40295737›Full record

ArticleNpj viruses2024

Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients.

Yvette den Hartog, S Reshwan K Malahe, Wim J R Rietdijk, Marjolein Dieterich, Lennert Gommers, Debbie van Baarle, Dimitri A Diavatopoulos, A Lianne Messchendorp, Renate G van der Molen, Ester B M Remmerswaal and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Npj viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yvette den HartogDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
S Reshwan K MalaheDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Wim J R RietdijkDepartment of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Marjolein DieterichDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Lennert GommersDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Debbie van BaarleDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, The Netherlands.
Dimitri A DiavatopoulosDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
A Lianne MesschendorpDepartment of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Renate G van der MolenDepartment of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Ester B M RemmerswaalDepartment of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Frederike J BemelmanRenal Transplant Unit, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Marcia M L KhoDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Corine H GeurtsvanKesselDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Marion P G KoopmansDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Ron T GansevoortDepartment of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Luuk B HilbrandsDepartment of Nephrology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
Jan-Stephan SandersDepartment of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Marlies E J ReindersDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Carla C BaanDepartment of Internal Medicine, Nephrology and Transplantation, Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Rory D de VriesDepartment of Viroscience, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. r.d.devries@erasmusmc.nl.
RECOVAC Consortium

Funding

Health~Holland EMCLHS20017Horizon 2020 101003589Nierstichting 21OP+036ZonMw 10150062010008ZonMw 10430072010002
6 · The paper itself

Abstract

Kidney transplant recipients (KTRs) are at an increased risk of severe COVID-19 due to compromised immune responses. Although vaccination is critical in preventing severe disease, KTRs have attenuated vaccination-induced immune responses due to underlying kidney disease and immunosuppressive therapies. In this study, the effect of different COVID-19 booster strategies on SARS-CoV-2-specific T-cell responses was assessed in KTRs who showed a poor serological response after the first two mRNA-based primary vaccination doses. In these KTRs, a third vaccination dose led to an increase in antibody levels in the majority of patients. Production of IL-2 and IL-5 by SARS-CoV-2 specific T cells positively correlated with antibody levels, with stronger correlations compared to IFN-γ production, the 'traditional' cytokine to measure T-cell responses. Our study underscores the significance a balanced T-cell cytokine response to achieve robust antibody responses in KTRs. Furthermore, we show that multiple cytokines to assess T-cell responses should be explored to identify individuals in need of tailored vaccination strategies.

Identifiers

PMID40295737
PMCPMC11702830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.